The Differences Between the Vaccines Matter

The Atlantic, March 7, 2021: Public-health officials are enthusiastic about all 3 COVID-19 vaccines available in the U.S. For example, Virginia’s vaccine coordinator stated, “A hundred percent efficacy against deaths and hospitalizations? That’s all I need to hear.” But experts, including NCHR, point out that there were too few people with severe COVID in the vaccine studies to draw conclusions.

Read More »

Drug Industry Pushes FDA to Solve Growing Inspection Backlog

Politico, March 2, 2021: The FDA is under pressure from the pharmaceutical industry to address the growing backlog of drug inspections — nearly a year after Covid-19 prompted the agency to halt most plant visits. From March through September, FDA inspected just three plants outside the U.S. and 52 within the U.S., well below the 600 and 400, respectively in each of the prior two years. NCHR president reports device inspections have also dropped dramatically

Read More »

What you need to know about J&J’s newly authorized one-shot COVID-19 vaccine

ScienceNews: February 27, 2021. On February 27, the FDA authorized Johnson & Johnson’s COVID-19 vaccine for use in the U.S. The other two authorized vaccines are made by Pfizer and Moderna. None are FDA approved. All show effectiveness, but there are too few serious COVID-19 cases in any of the studies to conclude how well it prevents hospitalizations or deaths.

Read More »

J&J COVID-19 Vaccine Wins Unanimous Backing of FDA Panel

Medscape Medical News: February 26, 2021. An FDA advisory panel lent their support today to a rapid clearance for Janssen/Johnson & Johnson’s COVID-19 vaccine, but several researchers expressed concerns to the panel about the lower standards of EUAs, including NCHR’s president Dr. Diana Zuckerman.

Read More »